

Amendment Tool

v1.2 11 Jun 2020

For office use

QC: No

Section 1: Project information

Short project title*:	PACKMaN			
IRAS project ID* (or REC reference if no IRAS project ID is available):	1003404			
Sponsor amendment reference number*:	Substantial Amendment 1			
Sponsor amendment date* (enter as DD/MM/YY):	23 October 2020			
Summary of amendment including justification*:	Amendment to the IMPD and EudraCT form to include intrasosseous route of administration of the IMP, as requested and agreed with the MHRA during initial approval.			
Project type:	<input checked="" type="radio"/> Specific study <input type="radio"/> Research tissue bank <input type="radio"/> Research database			
Has the study been reviewed by a UKECA-recognised Research Ethics Committee (REC) prior to this amendment?:	<input checked="" type="radio"/> Yes		<input type="radio"/> No	
What type of UKECA-recognised Research Ethics Committee (REC) review is applicable?:	<input checked="" type="radio"/> NHS/HSC REC <input type="radio"/> Ministry of Defence (MoDREC)			
Is all or part of this amendment being resubmitted to the Research Ethics Committee (REC) as a modified amendment?	<input type="radio"/> Yes		<input checked="" type="radio"/> No	
Where is the NHS/HSC Research Ethics Committee (REC) that reviewed the study based?:	England	Wales	Scotland	Northern Ireland
	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
Was the study a clinical trial of an investigational medicinal product (CTIMP) OR does the amendment make it one?:	<input checked="" type="radio"/> Yes		<input type="radio"/> No	
Was this clinical trial of an investigational medicinal product (CTIMP) processed under the Combined Ways of Working (CWoW) pilot?:	<input checked="" type="radio"/> Yes		<input type="radio"/> No	
Did the study receive Pharmacy Assurance?:	<input type="radio"/> Yes		<input checked="" type="radio"/> No	
Was the study a clinical investigation or other study of a medical device OR does the amendment make it one?:	<input type="radio"/> Yes		<input checked="" type="radio"/> No	
Did the study involve the administration of radioactive substances, therefore requiring ARSAC review, OR does the amendment introduce this?:	<input type="radio"/> Yes		<input checked="" type="radio"/> No	
Did the study involve the use of research exposures to ionising radiation (not involving the administration of radioactive substances) OR does the amendment introduce this?:	<input type="radio"/> Yes		<input checked="" type="radio"/> No	
Did the study involve adults lacking capacity OR does the amendment introduce this?:	<input checked="" type="radio"/> Yes		<input type="radio"/> No	
Did the study involve access to confidential patient information without consent OR does the amendment introduce this?:	<input type="radio"/> Yes		<input checked="" type="radio"/> No	
Did the study involve prisoners OR does the amendment introduce this?:	<input type="radio"/> Yes		<input checked="" type="radio"/> No	
Did the study involve NHS/HSC organisations prior to this amendment?:	<input checked="" type="radio"/> Yes		<input type="radio"/> No	
Did the study involve non-NHS/HSC organisations OR does the amendment introduce them?:	<input type="radio"/> Yes		<input checked="" type="radio"/> No	
	England	Wales	Scotland	Northern Ireland
Lead nation for the study:	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Which nations had participating NHS/HSC organisations prior to this amendment?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Which nations will have participating NHS/HSC organisations after this amendment?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Section 2: Summary of change(s)

What do you want to update?:	<input type="radio"/> Chief Investigator <input type="radio"/> Sponsor
------------------------------	---

What do you want to update? :

- Administrative
- Project information

Please note: Each change being made as part of the amendment must be entered separately. For example, if an amendment to a clinical trial of an investigational medicinal product (CTIMP) involves an update to the Investigator's Brochure (IB), affecting the Reference Safety Information (RSI) and so the information documents to be given to participants, these should be entered into the amendment tool as three separate changes. A list of all possible changes is available on the "Glossary of Changes" tab. To add another change, tick the "Add another change" box.

Change 1				
Area of change (select)*:	CTIMP documents			
Specific change (select - only available when area of change is selected first)*:	IB, IMPD, SmPC - Substantial changes (e.g. affecting the risk/benefit assessment, changes to the RSI)			
Further information (free text):	Update to the IMPD and EudraCT form to bring in line with the protocol.			
Applicability:	England	Wales	Scotland	Northern Ireland
Where are the participating NHS/HSC organisations located that will be affected by this change?*	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Will all participating NHS/HSC organisations be affected by this change, or only some?:	<input checked="" type="radio"/> All		<input type="radio"/> Some	

Add another change:

Section 3: Declaration(s) and lock for submission

Declaration by the Sponsor or authorised delegate

- I confirm that the Sponsor takes responsibility for the completed amendment tool
- I confirm that I have been formally authorised by the Sponsor to complete the amendment tool on their behalf

Name [first name and surname]*:	Mathew Gane
Email address*:	sponsorship@warwick.ac.uk

Lock for submission

Please note: This button will only become available when all mandatory (*) fields have been completed. When the button is available, clicking it will generate a PDF copy of the completed amendment tool that can be included in the amendment submission. Please ensure that the amendment tool is completed correctly before locking it for submission.

Lock for submission

After locking the tool, refer to the "Submission Guidance" tab for further information about the next steps for the amendment.

Section 4: Review bodies for the amendment

Please note: This section is for **information only**. Details in this section will complete automatically based on the options selected in Sections 1 and 2.

	Review bodies																Category:			
	UK wide:						England and Wales:				Scotland:			Northern Ireland:						
	REC	Competent Authority MHRA - Medicines	Competent Authority MHRA - Devices	ARSAC	Radiation Assurance	UKSW Governance	REC (MCA)	CAG	HMPPS	HRA and HCRW Approval	REC (AWIA)	PBPP	SPS (RAEC)	National coordinating function	HSC REC	HSC Data Guardians	Prisons	National coordinating function		
Change 1:	Y	Y				(Y)				(Y)										C
Overall reviews for the amendment:																				
Full review:	Y	Y				N				N										

Notification only:	N	N				Y				Y								
Overall amendment type:	Substantial for review																	
Overall Category:	C																	